Semaglutide vs Tirzepatide: GLP-1 Therapies Compared

If you are considering GLP-1-based therapy for weight management or metabolic health, you are almost certainly choosing between two medications: semaglutide (branded as Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (branded as Mounjaro for diabetes, Zepbound for weight loss). Both have transformed metabolic medicine. Both produce weight loss results that were unimaginable a decade ago. But they are not the same molecule, and the differences matter clinically.

Here is what the evidence shows, and how I think about this decision in practice.

At a Glance

How Semaglutide Works

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — it mimics the natural incretin hormone GLP-1, which is released from the gut after eating.

The incretin system: When you eat, your intestinal L-cells release GLP-1, which signals to the pancreas to produce insulin, suppresses glucagon secretion, slows gastric emptying, and signals satiety to the hypothalamus. Natural GLP-1 has a half-life of approximately 2 minutes — it is rapidly degraded by the enzyme DPP-4. Semaglutide is engineered with a fatty acid side chain and amino acid substitutions that extend its half-life to approximately 7 days, enabling once-weekly dosing.

Key physiological effects:

• Appetite suppression: GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger signaling. Patients consistently report a dramatic reduction in food preoccupation and cravings.
• Delayed gastric emptying: Food remains in the stomach longer, prolonging satiety after meals. This contributes to reduced caloric intake.
• Glucose-dependent insulin secretion: Insulin is released only when blood glucose is elevated, minimizing hypoglycemia risk.
• Glucagon suppression: Reduced hepatic glucose output, improving fasting glucose levels.
• Potential cardiovascular benefits: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients with obesity treated with semaglutide 2.4 mg (Lincoff et al., 2023).

The weight loss data:

The STEP trial program established semaglutide’s weight loss efficacy:

• STEP 1: 2.4 mg semaglutide produced 14.9% body weight loss vs. 2.4% with placebo over 68 weeks in adults with obesity (Wilding et al., 2021).
• STEP 2: In patients with type 2 diabetes, 2.4 mg semaglutide produced 9.6% weight loss vs. 3.4% with placebo. Weight loss is consistently lower in diabetic populations.
• STEP 3: Combined with intensive behavioral therapy, semaglutide produced 16% weight loss.
• STEP 5: Over 2 years, weight loss was maintained at approximately 15.2%.

How Tirzepatide Works

Tirzepatide is fundamentally different: it is the first approved dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist — sometimes called a “twincretin.”

Why GIP matters: GIP is the other major incretin hormone, released primarily from K-cells in the duodenum and jejunum. Historically, GIP was considered less therapeutically interesting because GIP receptor signaling appears blunted in type 2 diabetes. Tirzepatide challenged this assumption by demonstrating that pharmacological GIP agonism, combined with GLP-1 agonism, produces metabolic effects that exceed what GLP-1 alone can achieve.

The dual mechanism:

• GLP-1 receptor agonism: The same appetite-suppressing, insulin-stimulating, gastric-emptying-delaying effects described for semaglutide.
• GIP receptor agonism: Enhances insulin secretion through a complementary pathway, improves lipid metabolism, and may have direct effects on adipose tissue. GIP receptor activation in fat tissue appears to improve fat cell insulin sensitivity and enhance lipid storage capacity, potentially reducing ectopic fat deposition in liver and muscle.
• Synergistic signaling: The combination of GLP-1 and GIP receptor activation produces insulin secretion enhancement that is greater than the sum of the individual effects — true pharmacological synergy.

The weight loss data:

The SURMOUNT trial program established tirzepatide’s weight loss efficacy — and the numbers were unprecedented:

• SURMOUNT-1: Tirzepatide at the highest dose (15 mg) produced 22.5% body weight loss vs. 2.4% with placebo over 72 weeks in adults with obesity without diabetes (Jastreboff et al., 2022). At the 10 mg dose: 19.5%. At 5 mg: 15%.
• SURMOUNT-2: In patients with type 2 diabetes and obesity, tirzepatide 15 mg produced 14.7% weight loss — notably higher than what semaglutide achieves in comparable diabetic populations.
• SURMOUNT-3: With intensive behavioral therapy, tirzepatide 15 mg produced 26.6% body weight loss.
• SURMOUNT-4: Demonstrated sustained efficacy — patients who continued tirzepatide maintained weight loss, while those switched to placebo regained.

Head-to-Head Comparison

The SURPASS-2 Trial

This is the most important study in this comparison. SURPASS-2 directly compared tirzepatide to semaglutide 1 mg (the diabetes dose, not the 2.4 mg weight loss dose) in patients with type 2 diabetes. Tirzepatide at all three doses (5, 10, and 15 mg) outperformed semaglutide 1 mg for both HbA1c reduction and weight loss (Frias et al., 2021).

• Tirzepatide 15 mg: -2.46% HbA1c reduction, -12.4 kg weight loss
• Tirzepatide 10 mg: -2.37% HbA1c reduction, -11.2 kg weight loss
• Tirzepatide 5 mg: -2.09% HbA1c reduction, -7.8 kg weight loss
• Semaglutide 1 mg: -1.86% HbA1c reduction, -6.2 kg weight loss

Important caveat: This trial used semaglutide at the 1 mg diabetes dose, not the 2.4 mg weight-management dose. A true head-to-head at maximum weight-loss doses has not been published as of this writing. However, cross-trial comparisons (which carry methodological limitations) consistently suggest tirzepatide at 15 mg outperforms semaglutide at 2.4 mg by approximately 5-7 percentage points of body weight loss.

Detailed Parameter Comparison

When I Recommend Semaglutide

Semaglutide remains the right choice in several clinical scenarios:

• Cardiovascular risk reduction as a primary goal — the SELECT trial is the landmark study. Semaglutide is the only GLP-1 therapy with a completed, published cardiovascular outcomes trial showing MACE reduction in non-diabetic obesity. Until tirzepatide’s cardiovascular outcomes data matures, semaglutide carries this evidence advantage.
• Patients who respond well to GLP-1 monotherapy — not every patient needs dual-incretin therapy. Some patients achieve their target weight and metabolic goals on semaglutide alone. If the response is adequate, there is no clinical reason to switch.
• Cost or insurance considerations — semaglutide has been available longer and may have better insurance formulary placement or manufacturer coupon programs in certain markets.
• Patients already established on semaglutide with good tolerance and results — I do not switch patients who are succeeding on semaglutide merely because a newer option exists. Medication adherence benefits from stability.
• Oral formulation preference — semaglutide is available as a daily oral tablet (Rybelsus) for patients who cannot tolerate injections. Tirzepatide does not currently have an oral formulation, though one is in development.

What I tell my patients: semaglutide is not the second-best option. It is an excellent medication with the most cardiovascular outcomes data and millions of patient-years of real-world experience. If it is working for you, there is no reason to change.

When I Recommend Tirzepatide

Tirzepatide tends to be my recommendation when:

• Maximum weight loss is the therapeutic priority — for patients with BMI above 35-40, patients for whom a 15% weight loss would be clinically insufficient, or patients who need to lose a substantial amount of weight to become surgical candidates or address weight-related comorbidities.
• Semaglutide has produced an inadequate response — some patients plateau at 10-12% weight loss on semaglutide. Switching to tirzepatide’s dual-incretin mechanism can break through that plateau in many cases.
• Type 2 diabetes with suboptimal glycemic control — tirzepatide’s superior HbA1c reduction in SURPASS-2 is clinically meaningful. For patients not achieving glycemic targets on GLP-1 monotherapy, the addition of GIP agonism offers a distinct benefit.
• Metabolic syndrome with prominent dyslipidemia — tirzepatide’s effects on triglycerides and insulin sensitivity appear superior to semaglutide’s, which matters for patients with the full metabolic syndrome phenotype.
• Patients experiencing significant GI side effects on semaglutide — this is counterintuitive, but some patients tolerate tirzepatide better than semaglutide despite its greater potency. The GIP component may have gastroprotective effects that partially offset GLP-1-mediated nausea.

Here is what the evidence shows: in every metric measured in published trials — weight loss, HbA1c reduction, and proportion of patients reaching clinically meaningful thresholds — tirzepatide outperforms semaglutide. The evidence advantage for semaglutide is in cardiovascular outcomes data and longer market experience.

Can You Combine Them?

No — and this is important. Semaglutide and tirzepatide should not be combined. Both activate the GLP-1 receptor. Using both would produce additive GLP-1 stimulation without clinical benefit, dramatically increasing GI side effects and hypoglycemia risk. You choose one or the other.

What about combining with other agents?

Both semaglutide and tirzepatide can be combined with:

• Metformin — complementary mechanisms; standard combination for type 2 diabetes.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) — additive metabolic and cardiovascular benefits. This is an increasingly common and well-supported combination.
• Insulin — for patients with advanced type 2 diabetes, though the GLP-1/GIP agonist typically reduces insulin requirements significantly.

The emerging frontier is combining GLP-1-based therapy with other peptides — specifically amylin analogs (cagrilintide) or glucagon receptor agonists. Novo Nordisk’s CagriSema (cagrilintide + semaglutide) has shown weight loss approaching 25% in trials, narrowing the gap with tirzepatide. Eli Lilly’s retatrutide (triple agonist: GLP-1/GIP/glucagon) has shown weight loss exceeding 24% in phase 2 trials. This next generation may reshape the comparison landscape entirely.

Clinical Perspective — Julian Douwes M.D.

The semaglutide vs tirzepatide decision is one I discuss with patients almost daily. My approach is pragmatic: if a patient presents with obesity and cardiovascular risk as the primary concern, semaglutide’s SELECT trial data gives it an evidence edge that I weigh heavily. If maximum weight loss is the goal and the patient has no prior response to a GLP-1 agent, I lean toward tirzepatide from the start. What I emphasize to every patient is that neither medication is a standalone solution. Without concurrent attention to nutrition quality, resistance training to preserve lean mass, sleep optimization, and behavioral change, the weight will return when the medication stops. These drugs create a window of opportunity. What you build during that window determines the long-term outcome.

Key Takeaways

• Semaglutide is a GLP-1 receptor agonist producing 15-17% body weight loss at the 2.4 mg dose, with proven cardiovascular benefit (SELECT trial).
• Tirzepatide is a dual GLP-1/GIP receptor agonist producing 20-25% body weight loss at the 15 mg dose, with superior glycemic control in head-to-head trials.
• Tirzepatide outperforms semaglutide in weight loss and HbA1c reduction in published data, though a true maximum-dose head-to-head trial is pending.
• Semaglutide has the advantage in cardiovascular outcomes evidence and longer real-world experience.
• GI side effects (nausea, vomiting, diarrhea) are common with both medications and typically improve with proper dose titration.
• The two should never be combined — choose one based on clinical goals, prior response, and the evidence profile that matters most for the individual patient.
• Neither medication replaces lifestyle intervention. Nutrition, exercise, sleep, and behavioral change remain foundational.

References

1. Wilding, J.P.H., et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine, 384(11), 2021, pp. 989-1002.
2. Jastreboff, A.M., et al. “Tirzepatide once weekly for the treatment of obesity.” New England Journal of Medicine, 387(3), 2022, pp. 205-216.
3. Frias, J.P., et al. “Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.” New England Journal of Medicine, 385(6), 2021, pp. 503-515.
4. Lincoff, A.M., et al. “Semaglutide and cardiovascular outcomes in obesity without diabetes.” New England Journal of Medicine, 389(24), 2023, pp. 2221-2232.
5. Rosenstock, J., et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial.” The Lancet, 402(10401), 2023, pp. 529-544.